Hara Capital’s ResMed RMD Stock Holding History

Hara Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$209K	Hold	930	–	–	0.1%	123
2025 Q4	$224K	Hold	930	–	–	0.12%	118
2025 Q3	$255K	Hold	930	–	–	0.15%	106
2025 Q2	$240K	Hold	930	–	–	0.15%	116
2025 Q1	$208K	Sell	930 -930	-50%	-$217K	0.14%	118
2024 Q4	$425K	Buy	1,860 +930	+100%	+$224K	0.14%	121
2024 Q3	$227K	Buy	+930	New	+$208K	0.14%	115

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hara Capital's RMD Position: Q1 2026 in Review

Hara Capital held its ResMed (RMD) position steady in Q1 2026 at 930 shares worth $209K. The position accounts for 0.1% of the portfolio, ranked #123.

Hara Capital first reported a position in RMD in Q3 2024 and has held it in 7 quarters since. The position peaked at $425K in Q4 2024. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Hara Capital held 930 shares of ResMed worth $209K as of Q1 2026.
Hara Capital left its ResMed share count unchanged in Q1 2026.
ResMed made up 0.1% of Hara Capital's portfolio in Q1 2026, its #123 holding.
Hara Capital first reported a position in ResMed in Q3 2024 and has held it in 7 quarters since.
Hara Capital's ResMed position peaked at $425K in Q4 2024.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Hara Capital's 13F filing for Q1 2026, filed 14 May 2026.